Ozempic for insulin resistance: what TikTok gets right and wrong

What did @teloresuelvo_ok actually say?

Honestly? It's hard to say. The transcript from this video is largely incoherent, a string of disconnected phrases like "we'll have to solve it" and references to "the West Side" and "the city's news" that don't map onto any recognizable medical claim about GLP-1 medications, type 2 diabetes, or insulin resistance. No verifiable health statement was made in the content we reviewed.

The hashtags tell a different story than the words. The creator tagged #ozempick, #diabetestipo2, and #resistenciaainsulina, which signals intent to reach an audience searching for information on semaglutide and metabolic health. But the spoken content, at least as captured in this transcript, does not deliver any coherent claim about those topics. Whether the transcript is a transcription error, a translation artifact from Spanish, or reflects actual video content is impossible to determine from what was provided.

This matters because TikTok's algorithm surfaces content based on hashtags, not accuracy. Someone searching for diabetes guidance could land on this video regardless of whether it contains useful information.

Does the science back this up?

There is nothing specific to back up or refute here. No medical claim was made. But since the hashtags invoke GLP-1 medications and insulin resistance, it's worth grounding this in what the evidence actually shows, because the audience arriving via those hashtags deserves real context.

Semaglutide, the active ingredient in Ozempic and Wegovy, works by mimicking GLP-1, a gut hormone that stimulates insulin secretion, suppresses glucagon, and slows gastric emptying. The SUSTAIN and STEP trial series (Marso et al., 2016, New England Journal of Medicine; Wilding et al., 2021, NEJM) demonstrated clinically significant reductions in HbA1c and body weight in patients with type 2 diabetes and obesity, respectively. Insulin resistance is a core driver of type 2 diabetes pathology, and GLP-1 receptor agonists address it indirectly through weight loss and improved beta-cell function, not through a direct insulin-sensitizing mechanism like metformin or thiazolidinediones.

That nuance matters. Conflating "helps insulin resistance" with "fixes insulin resistance" is a common and misleading shortcut in GLP-1 content online.

What did they get wrong (or right)?

This is genuinely hard to assess because the transcript doesn't yield a coherent claim. What we can say is this: the creator got the hashtag strategy right for reach, and completely wrong for responsibility. Tagging content with clinical terms like #resistenciaainsulina while delivering no substantive medical information is a pattern that floods health search results with noise.

If this video contains Spanish-language medical advice that wasn't accurately transcribed, that's a separate and serious issue. Spanish-speaking communities searching for GLP-1 information on TikTok are already underserved by quality health content. Creators who occupy that hashtag space with unclear or unverifiable content are taking up room that accurate information could fill.

Nothing in the transcript reflects an outright dangerous claim, but nothing reflects a useful or accurate one either. The closest thing to a takeaway, "the best way to do it is to make the person feel comfortable," is too vague to evaluate medically. That's not a fact-check pass. That's an absence of facts.

What should you actually know?

If you landed here because you were searching for information about Ozempic, type 2 diabetes, or insulin resistance, here is what the evidence actually supports.

• Semaglutide is FDA-approved for type 2 diabetes management (Ozempic) and chronic weight management (Wegovy) in adults with obesity or overweight with a weight-related condition. These are distinct indications with different approved doses.
• GLP-1 receptor agonists are not a cure for insulin resistance or type 2 diabetes. They are management tools. Davies et al. (2021, Diabetes Care) showed sustained glycemic benefit with continued use, and loss of that benefit after discontinuation.
• Compounded semaglutide is not the same as branded Ozempic or Wegovy. Formulation, purity testing, and dosing accuracy differ. The FDA has issued repeated warnings about compounded GLP-1 products.
• Anyone considering GLP-1 therapy for diabetes or weight management should do so under supervision of a licensed clinician who can assess contraindications, including personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• TikTok hashtags like #ozempick are not a substitute for a clinical consultation. The algorithm does not filter for accuracy.